AVITA Medical

Name: AVITA Medical
Address: 28159 Avenue Stanford, Valencia, CA, 91355, US
Telephone: +16613679170
Price range: Not Applicable

AVITA Medical (NASDAQ: RCEL, ASX:AVH) is a leading therapeutic acute wound care company delivering transformative solutions.

Our technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering a groundbreaking so

lution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

08/28/2026

Delayed wound grafting can have lasting impacts to physicians, hospitals, and patients.

Now you can influence predictable wound bed preparation and support earlier graft readiness with Cohealyx® collagen dermal matrix.

Built for speed. Designed for confidence.

Learn more: https://na2.hubs.ly/H07wb4z0

08/26/2026

The goal in burn care is to achieve timely wound closure while optimizing functional and aesthetic outcomes and minimizing downstream burden. Delaying definitive closure can prolong open-wound burden by impacting clinical, patient, and operational outcomes.

Learn how RECELL® Spray-On Skin™ Cells can support wound treatment by changing the timing trajectory. Compared to conservative treatment, early RECELL use in a patient's course of deep-partial thickness burn treatment supports:

- Increased re-epithelialization (1)
- Less scarring (1)
- Reduced need for surgery (2)
- Fewer dressing changes (1,2)

Learn more: https://na2.hubs.ly/H07p4_G0

1. Maxey J et al. J Pediatr Surg Open. 2025;11:100215. doi:10.1016/j.yjpso.2025.100215
2. Wood F, Martin L, Lewis D, Rawlins J, McWilliams T, Burrows S, Rea S. Burns. 2012 Sep;38(6):830-9.

08/25/2026

Deep partial-thickness burns present a common clinical challenge in burn care. As clinicians evaluate whether these wounds will progress, delays in definitive treatment can prolong hospitalization, increase treatment burden, and contribute to scarring and functional concerns.

Join the American Burn Association (ABA) for a special webinar highlighting the role of RECELL® in the management of deep partial-thickness burns, drawing on clinical experience, case-based insights, and growing real-world evidence.

Dr. Jonathan Schoen and Dr. Victoria Miles will share practical perspectives from their experience treating burn patients with RECELL, including cases that demonstrate rapid healing, functional recovery, pigmentation, and aesthetic outcomes.

DATE: Wednesday, September 2, 2026
TIME: 3:00 PM - 4:00 PM CDT

Register here: https://na2.hubs.ly/H07p5Nq0

08/24/2026

Real-world evidence: Reduced length of stay with RECELL® Spray-On Skin™ Cells

The American Burn Association’s registry, Burn Care Quality Platform, contains greater than 8,500 U.S. patients treated with RECELL® Spray-On Skin™ Cells between 2019 and 2024. Using this registry, a retrospective matched-cohort analysis demonstrated that the use of RECELL Spray-On Skin Cells significantly reduces hospital length of stay compared to traditional autografting, equating to measurable savings per patient.

Learn more about RECELL: https://na2.hubs.ly/H07p5JJ0

08/21/2026

At the Michigan Academy of Plastic Surgeons annual meeting, Vania Arboleda Mocarro, DO, presented a case study demonstrating the use of Cohealyx® collagen dermal matrix followed by RECELL® Spray-On Skin™ Cells to facilitate reconstruction after oncologic excision.

In a 70-year-old patient with multiple comorbidities and a complex, tendon-exposed wound, Cohealyx established a well-vascularized wound bed within 7 days, enabling definitive closure with RECELL and a meshed split-thickness skin graft. The patient achieved 100% graft take at one week, complete re-epithelialization by two weeks, and excellent functional and aesthetic outcomes without complications.

This case highlights Cohealyx and RECELL as tools to support early wound closure and optimize outcomes in patients with complex full-thickness wounds.

08/20/2026

Today is the day! Did you save your seat?

Join the American Burn Association today for an online education event: The Evolving Landscape of Temporary Wound Coverage.

DATE: Thursday, August 20, 2026
TIME: 3:00 PM - 4:00 PM CDT

It's not too late! Register now: https://na2.hubs.ly/H07kHmx0

08/17/2026

Join the American Burn Association this Thursday for an exciting new webinar: The Evolving Landscape of Temporary Wound Coverage. Don't miss this event featuring three industry-leading surgeon presenters.

DATE: Thursday, August 20, 2026
TIME: 3:00 PM - 4:00 PM CDT

Register here: https://na2.hubs.ly/H07dwX_0

08/14/2026

Cohealyx® collagen dermal matrix is changing the way physicians approach wound closure. Watch Carmen Flores, MD, discuss how it differs from other dermal matrices, features that make it easy to work with, and how it supports wound healing.

08/12/2026

Move faster with Cohealyx® collagen dermal matrix.

Engineered to meet real-world challenges of prolonged wound bed preparation, Cohealyx was designed to support cellular migration and revascularization—helping prepare wounds for closure as early as day 5.(1,2)

Graft sooner with Cohealyx.

Get started: https://na2.hubs.ly/H078bYS0

1. https://na2.hubs.ly/H0787pD0 identifier: NCT06787690. Interim Analysis. Publication in Progress. 2. Akpunonu C, et al. J Surg. 2025;10(07):11337.

08/11/2026

It's not too late to register! Join the American Burn Association for an online education presentation detailing a multicenter randomized controlled trial and real-world clinical experience with PermeaDerm®, a temporary biosynthetic wound matrix used as a cost-effective alternative to allograft.

DATE: Thursday, August 20, 2026
TIME: 3:00 PM - 4:00 PM CDT

Register here: https://na2.hubs.ly/H0763S30

Address

28159 Avenue Stanford
Valencia, CA
91355

Telephone

+16613679170

Website

https://avitamedical.com/, https://ir.avitamedical.com/

Alerts

Be the first to know and let us send you an email when AVITA Medical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to AVITA Medical:

Want your business to be the top-listed Business in Valencia?